Screener / SEC EDGAR /CIK 0001745999 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Beam Therapeutics Inc. BEAM

Compare with peers Embed

BEAM among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+120%6th of 155 · median +10.5%
Net margin
-4.1%15.3%
-73.9%143rd of 154 · median 6.8%
Return on equity
-5.2%18.5%
-11.4%114th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-271.6%139th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.1111th of 108 · median 0.69

BEAM and 9 peers, year by year

The 9 Health care companies closest to BEAM in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthOperating marginNet marginFCF marginReturn on equityDebt / equity
BEAM Beam Therapeutics Inc. FY2025 $139.7M+120%−274.6%−57.2%−257.7%−6.5%-
AGIO Agios Pharmaceuticals, Inc. FY2025 $54.0M+48.0%−873.9%−764.0%−698.3%−34.6%-
GRAL GRAIL, Inc. FY2025 $147.2M+17.2%−382.0%−277.5%−203.8%−15.8%-
CYTK Cytokinetics Inc FY2025 $88.0M+377%−695.4%−891.6%−607.5%n/mn/m
KYMR Kymera Therapeutics, Inc. FY2025 $39.2M−16.7%−891.1%−794.0%−597.6%−19.7%-
RVMD Revolution Medicines, Inc. FY2025 $0----−69.3%-
RXRX Recursion Pharmaceuticals, Inc. FY2025 $74.7M+26.9%−867.9%−863.4%−506.5%−57.0%0.02
OCUL Ocular Therapeutix, Inc FY2025 $52.0M−18.5%−519.8%−511.9%−417.5%−40.6%0.11
ROIV Roivant Sciences Ltd. FY2026 $8.3M−71.6%n/mn/mn/m−6.6%-
LGND Ligand Pharmaceuticals Inc FY2025 $268.1M+60.4%15.3%46.4%18.2%12.2%-

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2019 to FY2025 · 10-K XBRL

BEAMBeam Therapeutics Inc.
FY2019 revenue $18KFY2020 revenue $24KFY2021 revenue $51.8MFY2022 revenue $60.9MFY2023 revenue $377.7MFY2024 revenue $63.5MFY2025 revenue $139.7M FY2021 net margin −714.9%FY2022 net margin −474.5%FY2023 net margin −35.1%FY2024 net margin −593.1%FY2025 net margin −57.2% FY2019FY2025
Revenue$139.7M Growth+120% Net margin−57.2%
AGIOAgios Pharmaceuticals, Inc.
FY2019 revenue $117.9MFY2022 revenue $14.2MFY2023 revenue $26.8MFY2024 revenue $36.5MFY2025 revenue $54.0M FY2019 net margin −349.0%FY2025 net margin −764.0% FY2019FY2025
Revenue$54.0M Growth+48.0% Net margin−764.0%
GRALGRAIL, Inc.
FY2022 revenue $55.5MFY2023 revenue $93.1MFY2024 revenue $125.6MFY2025 revenue $147.2M FY2025 net margin −277.5% FY2019FY2025
Revenue$147.2M Growth+17.2% Net margin−277.5%
CYTKCytokinetics Inc
FY2019 revenue $26.9MFY2020 revenue $55.8MFY2021 revenue $70.4MFY2022 revenue $94.6MFY2023 revenue $7.5MFY2024 revenue $18.5MFY2025 revenue $88.0M FY2019 net margin −452.9%FY2020 net margin −228.0%FY2021 net margin −305.7%FY2022 net margin −411.2%FY2025 net margin −891.6% FY2019FY2025
Revenue$88.0M Growth+377% Net margin−891.6%
KYMRKymera Therapeutics, Inc.
FY2019 revenue $2.9MFY2020 revenue $34.0MFY2021 revenue $72.8MFY2022 revenue $46.8MFY2023 revenue $78.6MFY2024 revenue $47.1MFY2025 revenue $39.2M FY2020 net margin −134.0%FY2021 net margin −137.6%FY2022 net margin −330.6%FY2023 net margin −187.0%FY2024 net margin −475.6%FY2025 net margin −794.0% FY2019FY2025
Revenue$39.2M Growth−16.7% Net margin−794.0%
RVMDRevolution Medicines, Inc.
FY2019 revenue $50.0MFY2020 revenue $43.0MFY2021 revenue $29.4MFY2022 revenue $35.4MFY2023 revenue $11.6M FY2019 net margin −95.2%FY2020 net margin −251.6%FY2021 net margin −636.6%FY2022 net margin −703.0% FY2019FY2025
Revenue$0 Growth−100% Net margin−703.0%
RXRXRecursion Pharmaceuticals, Inc.
FY2019 revenue $2.3MFY2020 revenue $4.0MFY2021 revenue $10.2MFY2022 revenue $39.8MFY2023 revenue $44.6MFY2024 revenue $58.8MFY2025 revenue $74.7M FY2022 net margin −601.0%FY2023 net margin −736.0%FY2024 net margin −788.0%FY2025 net margin −863.4% FY2019FY2025
Revenue$74.7M Growth+26.9% Net margin−863.4%
OCULOcular Therapeutix, Inc
FY2019 revenue $4.2MFY2020 revenue $17.4MFY2021 revenue $43.5MFY2022 revenue $51.5MFY2023 revenue $58.4MFY2024 revenue $63.7MFY2025 revenue $52.0M FY2020 net margin −894.3%FY2021 net margin −15.1%FY2022 net margin −138.0%FY2023 net margin −138.1%FY2024 net margin −303.7%FY2025 net margin −511.9% FY2019FY2025
Revenue$52.0M Growth−18.5% Net margin−511.9%
ROIVRoivant Sciences Ltd.
FY2021 revenue $23.8MFY2022 revenue $55.3MFY2023 revenue $31.5MFY2024 revenue $32.7MFY2025 revenue $29.1M FY2025 net margin −592.0% FY2019FY2025
Revenue$29.1M Growth−11.2% Net margin−592.0%
LGNDLigand Pharmaceuticals Inc
FY2019 revenue $120.3MFY2020 revenue $163.6MFY2021 revenue $241.5MFY2022 revenue $196.2MFY2023 revenue $131.3MFY2024 revenue $167.1MFY2025 revenue $268.1M FY2019 net margin 523.2%FY2020 net margin −1.8%FY2021 net margin 23.7%FY2022 net margin −17.0%FY2023 net margin 39.7%FY2024 net margin −2.4%FY2025 net margin 46.4% FY2019FY2025
Revenue$268.1M Growth+60.4% Net margin46.4%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2019 to FY2025

Revenue as reported in the 10-K.

$0 $377.7M FY2019FY2020FY2021FY2022FY2023FY2024FY2025 AGIO: $117.9M, $0, $0, $14.2M, $26.8M, $36.5M, $54.0M AGIO GRAL: -, -, -, $55.5M, $93.1M, $125.6M, $147.2M GRAL CYTK: $26.9M, $55.8M, $70.4M, $94.6M, $7.5M, $18.5M, $88.0M CYTK KYMR: $2.9M, $34.0M, $72.8M, $46.8M, $78.6M, $47.1M, $39.2M KYMR RVMD: $50.0M, $43.0M, $29.4M, $35.4M, $11.6M, $0, $0 RVMD RXRX: $2.3M, $4.0M, $10.2M, $39.8M, $44.6M, $58.8M, $74.7M RXRX OCUL: $4.2M, $17.4M, $43.5M, $51.5M, $58.4M, $63.7M, $52.0M OCUL ROIV: -, -, $23.8M, $55.3M, $31.5M, $32.7M, $29.1M ROIV LGND: $120.3M, $163.6M, $241.5M, $196.2M, $131.3M, $167.1M, $268.1M LGND BEAM: $18K, $24K, $51.8M, $60.9M, $377.7M, $63.5M, $139.7M BEAM
BEAM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $377.7M. A gap is a year with no number. A ring marks where a line starts: GRAL, ROIV have no earlier 10-K here. ROIV, LGND: the line is cut where a later 10-K restates the year before (a spin-off or a merger), so the two years are not the same company.

Sales growth, FY2019 to FY2025

Revenue against the fiscal year before.

−100% +520% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 AGIO: +24.9%, −100%, -, -, +88.4%, +36.1%, +48.0% AGIO GRAL: -, -, -, -, +67.6%, +34.9%, +17.2% GRAL CYTK: −14.7%, +108%, +26.2%, +34.3%, −92.0%, +145%, +377% CYTK KYMR: -, n/m, +114%, −35.7%, +67.8%, −40.1%, −16.7% KYMR RVMD: +148%, −14.1%, −31.6%, +20.4%, −67.3%, −100%, - RVMD RXRX: -, +70.8%, +157%, +291%, +11.9%, +32.0%, +26.9% RXRX OCUL: +112%, +312%, +150%, +18.3%, +13.5%, +9.0%, −18.5% OCUL ROIV: -, -, -, +132%, +10.8%, +3.8%, −11.2% ROIV LGND: −52.2%, +55.0%, +47.7%, −18.8%, −33.1%, +27.3%, +60.4% LGND BEAM: -, +33.3%, n/m, +17.5%, +520%, −83.2%, +120% BEAM
BEAM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −100% to +520%. A gap is a year with no number. A ring marks where a line starts: BEAM, GRAL, KYMR, RXRX, ROIV have no earlier 10-K here.

Operating margin, FY2019 to FY2025

Operating income / revenue.

−891.1% 671.0% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 AGIO: −268.2%, -, -, n/m, n/m, n/m, −873.9% AGIO GRAL: -, -, -, n/m, n/m, n/m, −382.0% GRAL CYTK: −368.0%, −168.3%, −264.5%, −342.8%, n/m, n/m, −695.4% CYTK KYMR: n/m, −136.1%, −138.0%, −344.4%, −210.6%, −555.8%, −891.1% KYMR RVMD: −108.2%, −257.5%, −639.7%, −730.0%, n/m, -, - RVMD RXRX: n/m, n/m, n/m, −616.7%, −785.3%, −814.1%, −867.9% RXRX OCUL: n/m, −361.1%, −179.3%, −152.7%, −141.0%, −269.6%, −519.8% OCUL LGND: 671.0%, 22.9%, 43.0%, 1.5%, 9.1%, −13.5%, 15.3% LGND BEAM: n/m, n/m, −757.0%, −555.6%, −46.7%, −654.3%, −274.6% BEAM
BEAM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −891.1% to 671.0%. A gap is a year with no number. A ring marks where a line starts: BEAM, GRAL, KYMR, RXRX, OCUL have no earlier 10-K here.

Net margin, FY2019 to FY2025

Net income / revenue.

−894.3% 523.2% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 AGIO: −349.0%, -, -, n/m, n/m, n/m, −764.0% AGIO GRAL: -, -, -, n/m, n/m, n/m, −277.5% GRAL CYTK: −452.9%, −228.0%, −305.7%, −411.2%, n/m, n/m, −891.6% CYTK KYMR: n/m, −134.0%, −137.6%, −330.6%, −187.0%, −475.6%, −794.0% KYMR RVMD: −95.2%, −251.6%, −636.6%, −703.0%, n/m, -, - RVMD RXRX: n/m, n/m, n/m, −601.0%, −736.0%, −788.0%, −863.4% RXRX OCUL: n/m, −894.3%, −15.1%, −138.0%, −138.1%, −303.7%, −511.9% OCUL ROIV: -, -, n/m, n/m, n/m, n/m, −592.0% ROIV LGND: 523.2%, −1.8%, 23.7%, −17.0%, 39.7%, −2.4%, 46.4% LGND BEAM: n/m, n/m, −714.9%, −474.5%, −35.1%, −593.1%, −57.2% BEAM
BEAM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −894.3% to 523.2%. A gap is a year with no number. A ring marks where a line starts: BEAM, GRAL, KYMR, RXRX, OCUL, ROIV have no earlier 10-K here.

Free cash flow, FY2019 to FY2025

Cash from operations minus capital spending.

−$913.7M $119.9M FY2019FY2020FY2021FY2022FY2023FY2024FY2025 AGIO: −$382.6M, −$304.9M, −$413.1M, −$314.4M, −$297.1M, −$391.5M, −$377.3M AGIO GRAL: -, -, -, −$584.2M, −$608.7M, −$582.4M, −$299.9M GRAL CYTK: −$93.5M, −$2.1M, −$191.4M, −$310.9M, −$415.7M, −$399.8M, −$534.8M CYTK KYMR: $17.4M, $79.0M, −$130.5M, −$155.9M, −$137.3M, −$207.3M, −$234.3M KYMR RVMD: −$52.2M, −$103.0M, −$153.7M, −$235.2M, −$358.3M, −$567.7M, −$913.7M RVMD RXRX: −$61.0M, −$51.2M, −$198.4M, −$120.6M, −$299.7M, −$372.9M, −$378.3M RXRX OCUL: −$79.8M, −$54.4M, −$66.7M, −$63.3M, −$76.3M, −$136.0M, −$216.9M OCUL ROIV: -, -, −$557.9M, −$695.2M, −$856.1M, −$766.6M, −$844.0M ROIV LGND: −$31.9M, $50.1M, $70.0M, $119.9M, $46.1M, $95.2M, $48.9M LGND BEAM: −$84.5M, −$112.1M, −$113.1M, −$26.4M, −$182.9M, −$356.2M, −$360.0M BEAM
BEAM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$913.7M to $119.9M. A gap is a year with no number. A ring marks where a line starts: GRAL, ROIV have no earlier 10-K here.

FCF margin, FY2019 to FY2025

Free cash flow / revenue.

−698.3% 592.1% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 AGIO: −324.5%, -, -, n/m, n/m, n/m, −698.3% AGIO GRAL: -, -, -, n/m, −653.8%, −463.7%, −203.8% GRAL CYTK: −348.1%, −3.8%, −271.8%, −328.6%, n/m, n/m, −607.5% CYTK KYMR: 592.1%, 232.2%, −179.2%, −333.0%, −174.7%, −440.5%, −597.6% KYMR RVMD: −104.3%, −239.6%, −523.0%, −664.8%, n/m, -, - RVMD RXRX: n/m, n/m, n/m, −302.6%, −672.4%, −633.7%, −506.5% RXRX OCUL: n/m, −312.6%, −153.4%, −123.0%, −130.6%, −213.4%, −417.5% OCUL LGND: −26.5%, 30.6%, 29.0%, 61.1%, 35.1%, 57.0%, 18.2% LGND BEAM: n/m, n/m, −218.1%, −43.4%, −48.4%, −560.8%, −257.7% BEAM
BEAM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −698.3% to 592.1%. A gap is a year with no number. A ring marks where a line starts: BEAM, GRAL, RXRX, OCUL have no earlier 10-K here.

Return on equity, FY2019 to FY2025

Net income / shareholders' equity at the year end.

−112.3% 124.2% FY2019FY2020FY2021FY2022FY2023FY2024FY2025 AGIO: −64.2%, −81.9%, 124.2%, −21.1%, −43.4%, 43.7%, −34.6% AGIO GRAL: -, -, -, -, -, −81.0%, −15.8% GRAL CYTK: n/m, −112.3%, −88.3%, n/m, n/m, n/m, n/m CYTK KYMR: n/m, −16.1%, −21.8%, −31.6%, −37.2%, −26.8%, −19.7% KYMR RVMD: n/m, −22.8%, −31.0%, −36.3%, −23.9%, −26.5%, −69.3% RVMD RXRX: n/m, n/m, −34.3%, −49.3%, −70.8%, −44.8%, −57.0% RXRX OCUL: n/m, n/m, −7.4%, n/m, −88.6%, −61.4%, −40.6% OCUL ROIV: -, -, −45.0%, −51.0%, −87.2%, 72.9%, −3.7% ROIV LGND: 82.0%, −0.4%, 7.0%, −5.6%, 7.4%, −0.5%, 12.2% LGND BEAM: n/m, −79.2%, −44.8%, −39.4%, −13.5%, −51.4%, −6.5% BEAM
BEAM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −112.3% to 124.2%. A gap is a year with no number. A ring marks where a line starts: BEAM, GRAL, CYTK, KYMR, RVMD, RXRX, OCUL, ROIV have no earlier 10-K here.

Debt / equity, FY2019 to FY2025

Total debt / shareholders' equity at the year end.

0.00 0.72 FY2019FY2020FY2021FY2022FY2023FY2024FY2025 CYTK: n/m, 0.41, 0.19, n/m, n/m, n/m, n/m CYTK RXRX: -, n/m, 0.00, 0.00, 0.00, 0.03, 0.02 RXRX OCUL: n/m, 0.33, 0.28, 0.71, 0.72, 0.22, 0.11 OCUL ROIV: -, -, 0.09, 0.13, 0.32, 0.07, - ROIV
BEAM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 0.72. A gap is a year with no number. A ring marks where a line starts: CYTK, RXRX, OCUL, ROIV have no earlier 10-K here.
CompanyFY2019FY2020FY2021FY2022FY2023FY2024FY2025
BEAM Dec -------
AGIO Dec -------
GRAL Dec -------
CYTK Dec n/m0.410.19n/mn/mn/mn/m
KYMR Dec -------
RVMD Dec -------
RXRX Dec -n/m0.000.000.000.030.02
OCUL Dec n/m0.330.280.710.720.220.11
ROIV Mar --0.090.130.320.07-
LGND Dec -------
Peer median--0.140.130.320.07-

EPS (diluted), FY2019 to FY2025

Diluted earnings per share, on today's share count after splits.

−$173.89 $31.85 FY2019FY2020FY2021FY2022FY2023FY2024FY2025 AGIO: −$6.86, −$4.74, $26.55, −$4.23, −$6.33, $11.64, −$7.12 AGIO GRAL: -, -, -, −$173.89, −$47.21, −$63.54, −$11.11 GRAL CYTK: −$2.11, −$1.97, −$2.80, −$4.33, −$5.45, −$5.26, −$6.54 CYTK KYMR: −$24.28, −$3.15, −$2.09, −$2.87, −$2.52, −$2.98, −$3.69 KYMR RVMD: −$22.33, −$2.01, −$2.57, −$3.08, −$3.86, −$3.58, −$5.95 RVMD RXRX: −$2.87, −$3.99, −$1.49, −$1.36, −$1.58, −$1.69, −$1.44 RXRX OCUL: −$1.91, −$2.56, −$0.98, −$0.97, −$1.02, −$1.22, −$1.42 OCUL ROIV: -, -, −$1.28, −$1.26, −$1.42, $5.23, −$0.24 ROIV LGND: $31.85, −$0.18, $3.31, −$1.98, $2.94, −$0.22, $6.13 LGND BEAM: −$14.05, −$4.19, −$5.77, −$4.13, −$1.72, −$4.58, −$0.81 BEAM
BEAM is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$173.89 to $31.85. A gap is a year with no number. A ring marks where a line starts: GRAL, ROIV have no earlier 10-K here.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out BEAM and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: BEAM's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BEAM/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.